TickerFacts.

Galectin Therapeutics Inc (GALT): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2013-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

-$42.43M
Year ended 2024-12-31
2010-12-31: -$4.87M2011-12-31: -$10.40M2012-12-31: -$9.90M2013-12-31: -$12.10M2014-12-31: -$15.43M2015-12-31: -$20.08M2016-12-31: -$21.48M2017-12-31: -$16.25M2018-12-31: -$13.60M2019-12-31: -$13.44M2020-12-31: -$23.44M2021-12-31: -$30.18M2022-12-31: -$38.35M2023-12-31: -$38.07M2024-12-31: -$42.43M-$42.43M
2010-12-31 EBITDA (USD) 2024-12-31
Period endedEBITDAChange YoYSource filing
2024-12-31-$42.43Mn/m2026-03-31, From 2024-01-01
2023-12-31-$38.07Mn/m2025-03-31, From 2023-01-01
2022-12-31-$38.35Mn/m2024-03-29, From 2022-01-01
2021-12-31-$30.18Mn/m2023-03-30, From 2021-01-01
2020-12-31-$23.44Mn/m2022-03-31, From 2020-01-01
2019-12-31-$13.44Mn/m2021-03-31, From 2019-01-01
2018-12-31-$13.60Mn/m2020-03-16, From 2018-01-01
2017-12-31-$16.25Mn/m2019-03-06, From 2017-01-01
2016-12-31-$21.48Mn/m2018-03-29, From 2016-01-01
2015-12-31-$20.08Mn/m2017-03-28, From 2015-01-01
2014-12-31-$15.43Mn/m2016-03-15, From 2014-01-01
2013-12-31-$12.10Mn/c2016-03-15, From 2013-01-01
2012-12-31-$9.90Mn/m2015-03-18, From 2012-01-01
2011-12-31-$10.40Mn/m2013-03-29, From 2011-01-01
2010-12-31-$4.87Mn/a2012-03-30, From 2010-01-01